Fate Therapeutics Inc at Cowen IO Next Summit (Virtual) Transcript
Great. Good afternoon, everyone. My name is Tyler Van Buren, senior biotech analyst at Cowen. Thank you again for joining us for Cowen's 6th Annual IO Next Summit. For this next session, I'm going to be moderating a fireside chat with Fate Therapeutics, and it's my pleasure to introduce Ed Dulac, Fate's Chief Financial Officer. Ed, it's a privilege to have you here. Thank you very much for joining us.
Pleasure, Tyler. Thanks for having us.
Questions & Answers
(Conference Instructions) Now we'll go ahead and get into it. So Ed, I figured we'd start with SITC then move to ASH and then the Q1 R&D analyst event in order. So maybe starting with SITC and the solid tumor franchise, at a high level, why is Fate pursuing the combination of its iNKs with standard of care antibodies in solid tumors?
Yes. So I mean,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |